Preferred Label : vilanterol;
MeSH synonym : 4-(2-((6-((2-(((2,6-dichlorophenyl)methyl)oxy)ethyl)oxy)hexyl)amino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol;
Is substance : O;
UNII : 028LZY775B;
InChIKey : DAFYYTQWSAWIGS-DEOSSOPVSA-N;
Origin ID : C550468;
UMLS CUI : C2935023;
ATC code(s)
- Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Manual BTNT mappings - CISMeF
- MeSH term(s) associated for indexing
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
https://www.has-sante.fr/jcms/p_3332759/fr/trelegy-ellipta-furoate-de-fluticasone/-bromure-d-umeclidinium-/-trifenatate-de-vilanterol-bpco
2022
false
false
false
France
French
evaluation of the transparency committee
bromides
registries
chronic obstructive lung disease, nos
vilanterol
vilanterol trifenatate
bromide salt, nos
umeclidinium
vilanterol
pulmonary disease, chronic obstructive
bromination
halogenation
---
https://www.has-sante.fr/jcms/p_3332764/fr/elebrato-ellipta-furoate-de-fluticasone-/-bromure-d-umeclidinium-/-trifenatate-de-vilanterol-bpco
2022
false
false
false
France
drug combinations
vilanterol, umeclidinium bromide and fluticasone furoate
fluticasone furoate
umeclidinium
pulmonary disease, chronic obstructive
evaluation of the transparency committee
vilanterol
---
https://www.has-sante.fr/jcms/p_3191672/fr/laventair-ellipta
2020
false
false
false
France
vilanterol and umeclidinium bromide
umeclidinium
drug combinations
vilanterol
Vilanterol Trifenatate
evaluation of the transparency committee
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
---
https://www.has-sante.fr/jcms/p_3191669/fr/revinty-ellipta
2020
false
false
false
France
drug combinations
fluticasone furoate
vilanterol
fluticasone furoate-vilanterol trifenatate
vilanterol and fluticasone furoate
evaluation of the transparency committee
androstadienes
benzyl alcohols
chlorobenzenes
drug combinations
---
https://www.has-sante.fr/jcms/p_3191675/fr/anoro-ellipta
2020
false
false
false
France
drug combinations
umeclidinium
vilanterol
vilanterol and umeclidinium bromide
evaluation of the transparency committee
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
---
https://www.has-sante.fr/jcms/p_3191663/fr/relvar-ellipta
2020
false
false
false
France
drug combinations
fluticasone furoate
vilanterol
fluticasone furoate-vilanterol trifenatate
vilanterol and fluticasone furoate
evaluation of the transparency committee
androstadienes
benzyl alcohols
chlorobenzenes
drug combinations
---
https://www.ema.europa.eu/en/medicines/human/EPAR/temybric-ellipta
2019
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
fluticasone furoate
fluticasone furoate
glucocorticoids
glucocorticoids
umeclidinium
umeclidinium
muscarinic antagonists
muscarinic antagonists
vilanterol
vilanterol
pulmonary disease, chronic obstructive
product surveillance, postmarketing
vilanterol, umeclidinium bromide and fluticasone furoate
administration, inhalation
adult
aged
drug interactions
pregnancy
breast feeding
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
drug evaluation, preclinical
GSK573719
GSK573719
quinuclidines
quinuclidines
androstadienes
androstadienes
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes
---
https://www.has-sante.fr/portail/jcms/c_2964753/fr/elebrato-ellipta-trelegy-ellipta
2019
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
---
https://www.has-sante.fr/portail/jcms/c_2964750/fr/elebrato-ellipta-trelegy-ellipta
2019
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
---
https://www.has-sante.fr/portail/jcms/c_2847883/fr/elebrato-trelegy-ellipta
2018
false
false
false
France
French
vilanterol, umeclidinium bromide and fluticasone furoate
treatment outcome
drug combinations
glucocorticoids
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
bronchodilator agents
administration, inhalation
adult
evaluation of the transparency committee
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
---
https://www.has-sante.fr/portail/jcms/c_2862997/fr/relvar-ellipta-revinty-ellipta
2018
false
France
French
vilanterol
fluticasone furoate
drug combinations
treatment outcome
glucocorticoids
asthma
adult
adolescent
administration, inhalation
adrenergic beta-2 receptor agonists
androstadienes
benzyl alcohols
chlorobenzenes
vilanterol and fluticasone furoate
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
evaluation of the transparency committee
insurance, health, reimbursement
fluticasone furoate-vilanterol trifenatate
drug combinations
---
Elebrato Ellipta - fluticasone furoate / umeclidinium / vilanterol
https://www.ema.europa.eu/medicines/human/EPAR/Elebrato-Ellipta
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilanterol, umeclidinium bromide and fluticasone furoate
drug approval
europe
treatment outcome
vilanterol
fluticasone furoate
drug combinations
umeclidinium
glucocorticoids
glucocorticoids
muscarinic antagonists
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
administration, inhalation
product surveillance, postmarketing
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
androstadienes
---
Trelegy Ellipta fluticasone furoate / umeclidinium / vilanterol
https://www.ema.europa.eu/medicines/human/EPAR/Trelegy-Ellipta
2018
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilanterol, umeclidinium bromide and fluticasone furoate
drug approval
europe
treatment outcome
vilanterol
fluticasone furoate
drug combinations
umeclidinium
glucocorticoids
glucocorticoids
muscarinic antagonists
muscarinic antagonists
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
administration, inhalation
product surveillance, postmarketing
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Fluticasone
vilanterol
umeclidinium
fluticasone furoate
GSK573719
benzyl alcohols
chlorobenzenes
androstadienes
quinuclidines
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
androstadienes
---
http://www.has-sante.fr/portail/jcms/c_2754734/fr/revinty-ellipta
2017
false
false
false
France
French
treatment outcome
vilanterol
fluticasone furoate
drug combinations
vilanterol and fluticasone furoate
adult
pulmonary disease, chronic obstructive
administration, inhalation
glucocorticoids
bronchodilator agents
adrenergic beta-2 receptor agonists
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
evaluation of the transparency committee
insurance, health, reimbursement
benzyl alcohols
chlorobenzenes
androstadienes
---
https://minerva-ebp.be/FR/Article/2085
2017
false
false
false
false
Belgium
French
critical appraisal or critical reading
comparative study
fluticasone furoate
vilanterol
pulmonary disease, chronic obstructive
cardiovascular risk
cardiovascular diseases
placebos
androstadienes
benzyl alcohols
chlorobenzenes
---
http://www.has-sante.fr/portail/jcms/c_2754746/fr/laventair
2017
false
false
false
France
French
treatment outcome
umeclidinium
vilanterol
vilanterol and umeclidinium bromide
drug combinations
administration, inhalation
bronchodilator agents
pulmonary disease, chronic obstructive
adult
muscarinic antagonists
adrenergic beta-2 receptor agonists
evaluation of the transparency committee
insurance, health, reimbursement
GSK573719
benzyl alcohols
chlorobenzenes
quinuclidines
---
http://www.has-sante.fr/portail/jcms/c_2630429/fr/quelle-place-pour-les-associations-fixes-corticoide-/-beta-2-mimetique-de-longue-duree-d-action-dans-le-traitement-de-la-bronchopneumopathie-chronique-obstructive
2016
false
false
false
France
French
guidelines for drug use
pulmonary disease, chronic obstructive
drug combinations
formoterol and beclometasone
formoterol and budesonide
Budesonide, Formoterol Fumarate Drug Combination
administration, inhalation
Formoterol Fumarate
Fluticasone-Salmeterol Drug Combination
bronchodilator agents
salmeterol and fluticasone
vilanterol and fluticasone furoate
Fluticasone
vilanterol
beclomethasone
glucocorticoids
adrenergic beta-2 receptor agonists
treatment outcome
benzyl alcohols
chlorobenzenes
---
http://www.has-sante.fr/portail/jcms/c_2676741/fr/anoro
http://www.has-sante.fr/portail/jcms/c_2676741/fr/anoro-bromure-d-umeclidinium-/-vilanterol-anticholinergique-/-agoniste-beta2-adrenergique-de-longue-duree-d-action
2016
false
false
false
France
French
evaluation of the transparency committee
drug combinations
vilanterol and umeclidinium bromide
insurance, health, reimbursement
treatment outcome
pulmonary disease, chronic obstructive
adult
bronchodilator agents
guidelines for drug use
vilanterol
umeclidinium
vilanterol trifenatate
GSK573719
quinuclidines
benzyl alcohols
chlorobenzenes
---
https://minerva-ebp.be/fr/analyses-en-ligne/286
2015
false
true
false
minerva-ebm.be
Belgium
French
french abstract
scientific and technical information
Fluticasone
chlorobenzenes
benzyl alcohol
treatment outcome
asthma
asthma
vilanterol
---
https://www.ema.europa.eu/medicines/human/EPAR/Revinty-Ellipta
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
vilanterol
fluticasone furoate
fluticasone furoate
vilanterol
drug combinations
drug approval
europe
vilanterol and fluticasone furoate
asthma
child
adolescent
adult
pulmonary disease, chronic obstructive
administration, inhalation
glucocorticoids
glucocorticoids
bronchodilator agents
bronchodilator agents
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
drug monitoring
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
clinical trials as topic
drug evaluation, preclinical
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
benzyl alcohols
chlorobenzenes
androstadienes
androstadienes
benzyl alcohols
chlorobenzenes
---
https://www.ema.europa.eu/medicines/human/EPAR/Anoro
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
umeclidinium
vilanterol
vilanterol
vilanterol and umeclidinium bromide
umeclidinium
drug combinations
drug monitoring
product surveillance, postmarketing
drug approval
europe
administration, inhalation
bronchodilator agents
bronchodilator agents
pulmonary disease, chronic obstructive
adult
aged
drug interactions
pregnancy
breast feeding
muscarinic antagonists
muscarinic antagonists
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
clinical trials as topic
drug evaluation, preclinical
drug evaluation
GSK573719
GSK573719
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes
quinuclidines
quinuclidines
---
Summary Basis of Decision (SBD) for Anoro Ellipta
Umeclidinium bromide and vilanterol trifenatate 62.5 µg of umeclidinium (as umeclidinium
bromide) and 25 µg of vilanterol (as vilanterol trifenatate) Powder, oral inhalation
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00270
2014
false
false
false
Canada
French
English
summary of product characteristics
drug approval
canada
drug combinations
administration, inhalation
treatment outcome
drug evaluation
risk assessment
clinical trials as topic
vilanterol
vilanterol
vilanterol and umeclidinium bromide
umeclidinium
umeclidinium
bronchodilator agents
bronchodilator agents
Delayed-Action preparations
muscarinic antagonists
muscarinic antagonists
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
pulmonary disease, chronic obstructive
bronchitis, chronic
pulmonary emphysema
adult
aged
GSK573719
GSK573719
quinuclidines
quinuclidines
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes
---
https://www.ema.europa.eu/medicines/human/EPAR/Laventair
2014
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
umeclidinium
vilanterol
vilanterol
vilanterol and umeclidinium bromide
umeclidinium
drug combinations
drug monitoring
product surveillance, postmarketing
drug approval
europe
administration, inhalation
bronchodilator agents
bronchodilator agents
pulmonary disease, chronic obstructive
adult
aged
drug interactions
pregnancy
breast feeding
muscarinic antagonists
muscarinic antagonists
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
clinical trials as topic
drug evaluation, preclinical
GSK573719
GSK573719
benzyl alcohols
chlorobenzenes
benzyl alcohols
chlorobenzenes
quinuclidines
quinuclidines
---
Summary Basis of Decision (SBD) for Breo Ellipta
100 µg of fluticasone furoate and 25 µg of vilanterol (as vilanterol trifenatate)
Powder, oral inhalation
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00174
2013
false
Canada
French
English
vilanterol and fluticasone furoate
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
drug information
Respiratory form fluticasone + vilanterol (product)
drug approval
canada
fluticasone furoate
fluticasone furoate
drug combinations
glucocorticoids
glucocorticoids
vilanterol
vilanterol
administration, inhalation
pulmonary disease, chronic obstructive
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
bronchodilator agents
bronchodilator agents
treatment outcome
drug evaluation
anti-inflammatory agents
anti-inflammatory agents
clinical trials, phase iii as topic
risk assessment
androstadienes
androstadienes
benzyl alcohols
benzyl alcohols
chlorobenzenes
chlorobenzenes
---
https://www.ema.europa.eu/medicines/human/EPAR/Relvar-Ellipta
2013
false
United Kingdom
French
English
vilanterol
fluticasone furoate
drug combinations
drug approval
europe
treatment outcome
fluticasone furoate
glucocorticoids
glucocorticoids
vilanterol
asthma
adult
adolescent
pulmonary disease, chronic obstructive
summary of product characteristics
package leaflet
drug evaluation
syndication feed
administration, inhalation
product surveillance, postmarketing
drug monitoring
drug interactions
pregnancy
breast feeding
adrenergic beta-2 receptor agonists
adrenergic beta-2 receptor agonists
clinical trials, phase iii as topic
drug evaluation, preclinical
androstadienes
androstadienes
benzyl alcohols
benzyl alcohols
chlorobenzenes
chlorobenzenes
vilanterol and fluticasone furoate
Adrenocortical steroid therapy
Glucocorticoid therapy
corticosteroid therapy
fluticasone furoate-vilanterol trifenatate
fluticasone furoate-vilanterol trifenatate
drug combinations
drug combinations
---
